{
    "id": 1799,
    "name": "islet cell tumor",
    "source": "DOID",
    "definition": "A pancreatic cancer that is located_in the pancreatic islet cells. [url:http\\://en.wikipedia.org/wiki/Islets_of_Langerhans, url:http\\://en.wikipedia.org/wiki/Neuroendocrine_tumor]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "10165"
    ],
    "termId": "DOID:1799",
    "evidence": [
        {
            "id": 2473,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (RADIANT-3) that supported FDA approval, treatment with Afinitor (everolimus) prolonged progression-free survival (11.0 vs 4.6 months, HR=0.35, p<0.001) compared to placebo in patients with progressive pancreatic neuroendocrine tumors (PMID: 21306238; NCT00510068).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1799,
                "name": "islet cell tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15052,
                    "pubMedId": 21306238,
                    "title": "Everolimus for advanced pancreatic neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21306238"
                },
                {
                    "id": 15547,
                    "pubMedId": null,
                    "title": "Afinitor (everolimus) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 725,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with pancreatic neuroendocrine tumors homozygous for FGFR4 G388 demonstrated increased tumor reduction following Afinitor (everolimus) treatment compared to patients harboring FGFR4 G388R (25% vs. 9%; p=0.049), however, partial response rate did not differ significantly due to small sample size (PMID: 22986737).",
            "molecularProfile": {
                "id": 541,
                "profileName": "FGFR4 G388R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1799,
                "name": "islet cell tumor",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 444,
                    "pubMedId": 22986737,
                    "title": "The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22986737"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9841,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0326 inhibited AKT activation, decreased tumor growth, metastasis, and angiogenesis and increased lifespan in a transgenic mouse model of pancreatic neuroendocrine tumor (PMID: 27225693).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5252,
                "therapyName": "GDC-0326",
                "synonyms": null
            },
            "indication": {
                "id": 1799,
                "name": "islet cell tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7679,
                    "pubMedId": 27225693,
                    "title": "Therapeutic Benefit of Selective Inhibition of p110\u03b1 PI3-Kinase in Pancreatic Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27225693"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9842,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) inhibited AKT activation, reduced tumor burden, and increased lifespan in a transgenic mouse model of pancreatic neuroendocrine tumor (PMID: 27225693).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1799,
                "name": "islet cell tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7679,
                    "pubMedId": 27225693,
                    "title": "Therapeutic Benefit of Selective Inhibition of p110\u03b1 PI3-Kinase in Pancreatic Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27225693"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01465659",
            "title": "Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2040,
                    "therapyName": "Pazopanib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01525082",
            "title": "Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2073,
                    "therapyName": "Bevacizumab + Capecitabine + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01525550",
            "title": "A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors",
            "phase": "FDA approved",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01603004",
            "title": "Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01784861",
            "title": "VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1272,
                    "therapyName": "Everolimus + Vorolanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02031536",
            "title": "Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101918",
            "title": "Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 624,
                    "therapyName": "Aflibercept",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315625",
            "title": "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02831179",
            "title": "Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4463,
                    "therapyName": "Capecitabine + Temozolomide + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03736720",
            "title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9702,
                    "therapyName": "Fluorouracil + Leucovorin + MM-398",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03972488",
            "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1332,
                    "therapyName": "Octreotide acetate",
                    "synonyms": null
                },
                {
                    "id": 9508,
                    "therapyName": "lutetium Lu 177 dotatate + Octreotide acetate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04086485",
            "title": "Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8723,
                    "therapyName": "lutetium Lu 177 dotatate + Olaparib",
                    "synonyms": null
                }
            ]
        }
    ]
}